Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988618 · ClinicalTrials.gov registry record
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
A clinical trial of Prurigo Nodularis, sponsored by Galderma R&D.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT06988618: Recruiting study of Prurigo Nodularis, sponsored by Galderma R&D.
NCT06988618 is a study of Prurigo Nodularis that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 600 participants, above the 187-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (221% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06988618, a study of Prurigo Nodularis, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Primary Outcome
The IGA-CPG stage is an instrument used to assess the overall number and thickness of chronic prurigo lesions at a given time point, as determined by the physician. In this scale, nodules, papules, plaques, and other PN lesions are defined as pruriginous lesions or chronic prurigo lesions. A single score will be determined by the physician as follows: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), or 4 (severe). A higher score indicates severe chronic prurigo.
Conditions Studied
Study Locations (20)
Florida
- Galderma Investigational Site # 7087 - Coral Gables
- Galderma Investigational Site # 7063 - Cutler Bay
- Galderma Investigational Site # 7078 - Miami
- Galderma Investigational Site # 7070 - North Miami Beach
- Galderma Investigational Site # 7091 - Tampa
California
- Galderma Investigational Site # 7074 - Corona
- Galderma Investigational Site # 6836 - Fountain Valley
- Galderma Investigational Site # 8224 - Fremont
- Galderma Investigational Site # 7064 - Santa Monica
Arizona
- Galderma Investigational Site # 7077 - Phoenix
- Galderma Investigational Site # 7060 - Phoenix
- Galderma Investigational Site # 7067 - Tucson
Maryland
- Galderma Investigational Site # 8012 - Glendale
- Galderma Investigational Site # 7068 - Rockville
Alabama
- Galderma Investigational Site # 8893 - Birmingham
Colorado
- Galderma Investigational Site # 7061 - Castle Rock
Connecticut
- Galderma Investigational Site # 7059 - Fairfield
Illinois
- Galderma Investigational Site # 7058 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2027-11-30 |
What NCT06988618 shows while recruiting
NCT06988618 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 187-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (221% higher).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 0 interventions.
NCT06988618 names 20 study sites across 10 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06988618 about?
NCT06988618 is a clinical study titled "Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults". The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
What is the current status of trial NCT06988618?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-08-11. Estimated completion is 2027-11-30.
What conditions does trial NCT06988618 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
Who is sponsoring clinical trial NCT06988618?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988618 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06988618's enrollment target sits among peer trials
600 1st of 14 higher than 14 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI